Details of the Drug Combination

General Information of Drug Combination (ID: DCR57AE)

Drug Combination Name

Taxol SNX-2112

Indication

Disease Entry	Status	REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour	Investigative	[1]

Component Drugs

Taxol DMUOT9V

SNX-2112 DMB5A80

Small molecular drug

2D MOL

3D MOL is unavailable

3D MOL

High-throughput Screening Result

Testing Cell Line: ES2

Zero Interaction Potency (ZIP) Score: 5.96

Bliss Independence Score: 4.94

Loewe Additivity Score: 3.11

LHighest Single Agent (HSA) Score: 7.47

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Taxol

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Pancreatic cancer	2C10	Phase 3	[4]
Gastric adenocarcinoma	2B72	Phase 2	[5]
Ovarian cancer	2C73	Phase 2	[5]

Taxol Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Apoptosis regulator Bcl-2 (BCL-2)	TTJGNVC	BCL2_HUMAN	Modulator	[2]
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Modulator	[2]
------------------------------------------------------------------------------------

Indication(s) of SNX-2112

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[6]

SNX-2112 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Heat shock protein 90 alpha (HSP90A)	TT78R5H	HS90A_HUMAN	Inhibitor	[6]
------------------------------------------------------------------------------------

SNX-2112 Interacts with 14 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK)	OTLF4ZB1	IKKA_HUMAN	Decreases Expression	[7]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[7]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[7]
Endoplasmic reticulum chaperone BiP (HSPA5)	OTFUIRAO	BIP_HUMAN	Decreases Expression	[7]
Endoplasmin (HSP90B1)	OT02XLBR	ENPL_HUMAN	Decreases Expression	[7]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Expression	[7]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Expression	[7]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Expression	[7]
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Affects Localization	[7]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Decreases Expression	[7]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[7]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[7]
Heat shock protein 75 kDa, mitochondrial (TRAP1)	OTNG0L8J	TRAP1_HUMAN	Decreases Expression	[7]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Activity	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 14 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Breast and ovarian cancer syndrome	DCNZ06C	UWB1289+BRCA1	Investigative	[8]
Breast carcinoma	DCG6GFK	OCUBM	Investigative	[8]
Carcinoma	DCF49E1	OV90	Investigative	[8]
Carcinoma	DCS4BSH	MDAMB436	Investigative	[8]
Colon adenocarcinoma	DC9L7NX	LOVO	Investigative	[8]
Colon carcinoma	DCRIXV0	RKO	Investigative	[8]
Rectal adenocarcinoma	DCQZ3RL	SW837	Investigative	[8]
Adenocarcinoma	DCO160B	COLO320DM	Investigative	[9]
Adenocarcinoma	DCBAQG3	SW-620	Investigative	[9]
Amelanotic melanoma	DCAKJ2B	A2058	Investigative	[9]
Germ cell tumour	DCXRNYU	PA1	Investigative	[9]
Large cell lung carcinoma	DCWVYYX	NCI-H460	Investigative	[9]
Malignant melanoma	DC7F7VA	A375	Investigative	[9]
Malignant melanoma	DC0QXK4	HT144	Investigative	[9]
Malignant melanoma	DCDRR2F	RPMI7951	Investigative	[9]
Malignant melanoma	DCJX4O1	SKMEL30	Investigative	[9]
Malignant melanoma	DC80HQW	UACC62	Investigative	[9]
Mesothelioma	DCPXR49	MSTO	Investigative	[9]
Non small cell carcinoma	DCM1MOO	SKMES1	Investigative	[9]
Ovarian endometrioid adenocarcinoma	DCN603S	A2780	Investigative	[9]
Ovarian serous cystadenocarcinoma	DCKN6S7	SK-OV-3	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 21 DrugCom(s)

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010 Jan 14;53(1):3-17.
7	The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-B and disruption of mitochondria-dependent pathways. Chem Biol Interact. 2013 Sep 5;205(1):1-10. doi: 10.1016/j.cbi.2013.06.007. Epub 2013 Jun 15.
8	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
9	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.